UBS Group upgraded shares of Danaher (NYSE:DHR – Free Report) to a strong-buy rating in a research note released on Wednesday,Zacks reports.
Several other equities research analysts have also recently commented on DHR. Royal Bank Of Canada lifted their target price on Danaher from $200.00 to $215.00 and gave the company an “outperform” rating in a research note on Wednesday, July 22nd. DZ Bank initiated coverage on Danaher in a research note on Wednesday, June 3rd. They set a “buy” rating and a $210.00 price target on the stock. Piper Sandler initiated coverage on Danaher in a report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price target on the stock. HSBC lowered their price objective on Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Finally, TD Cowen cut their target price on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $228.91.
Check Out Our Latest Research Report on Danaher
Danaher Trading Down 0.1%
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. During the same period in the prior year, the firm earned $0.77 earnings per share. Danaher’s revenue was up 5.5% compared to the same quarter last year. As a group, equities analysts anticipate that Danaher will post 8.53 earnings per share for the current fiscal year.
Institutional Trading of Danaher
A number of hedge funds have recently modified their holdings of the company. California State Teachers Retirement System raised its holdings in Danaher by 18,856.0% in the second quarter. California State Teachers Retirement System now owns 184,571,691 shares of the conglomerate’s stock worth $35,157,216,000 after purchasing an additional 183,598,005 shares during the period. BlackRock Inc. bought a new stake in shares of Danaher in the 2nd quarter valued at $10,492,520,000. State Street Corp raised its stake in Danaher by 1.7% during the 4th quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock worth $6,345,529,000 after buying an additional 472,608 shares during the period. Capital International Investors raised its stake in Danaher by 8.9% during the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after buying an additional 1,487,768 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in Danaher by 10.4% during the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after acquiring an additional 1,542,310 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.
Danaher Company Profile
Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.
The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.
Further Reading
- Five stocks we like better than Danaher
- MarketBeat Week in Review – 09/07 – 09/11
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
